How Has The Plasma Fractionation Market Size Evolved In Recent Years?
The plasma fractionation market has seen considerable growth due to a variety of factors.
• The dimension of the plasma fractionation market has been expanding robustly over the past few years. The market value is projected to surge from $31.42 billion in 2024 to $34.44 billion in 2025, recording a compound annual growth rate (CAGR) of 9.6%.
Various factors contribute to this growth during the historical period, including the rising incidence of hemophilia and immune deficiency disorders, an increasing elderly population, growing demand for immunoglobulins, the expansion of plasma collection centers, and a spike in the number of surgical procedures.
What Are The Estimated Market Size And Expected Annual Growth Rates For Global Plasma Fractionation Market?
The plasma fractionation market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for plasma fractionation is anticipated to experience significant growth in the ensuing years, with projections suggesting it will reach a value of $51.56 billion by 2029, boasting a compound annual growth rate (CAGR) of 10.6%.
The expansion during the forecast interval is assumed to be driven by a surge in global healthcare spending, widespread use of plasma-derived medicinal products, escalated funding levels for research and development, the need for plasma in addressing neurological disorders and the broadening of plasma fractionation facilities. Key anticipated trends for the forecast duration encompass the advancement in fractionation technologies, a tilt towards albumin and immunoglobulin therapies, an uptick in demand for specialized plasma goods, a concentration on pathogen inactivation techniques, and meaningful collaborations and alliances in the plasma industry.
Which Key Drivers Are Propelling The Plasma Fractionation Market's Growth?
The plasma fractionation market is anticipated to expand due to the rising prevalence of chronic illnesses. Such diseases are characterized by their lasting period of 1 year or longer necessitating continual medical care and include conditions such as heart disease, cancer, and diabetes. Utilizing plasma products for treatment can decrease morbidity, enhance life quality, and provide cost-effectiveness, thereby boosting plasma fractionation demand. For example, a report from the US-based National Library of Medicine in January 2023 projected a 99.5% increase in individuals aged 50 and older with one or more chronic illnesses by 2050, reaching 142.66 million from 71.522 million in 2020 in the United States. This surge in chronic conditions is propelling the healthcare analytical testing service market's growth. Hence, an escalating number of chronic diseases across all age groups is predicted to drive the growth of the plasma fractionation market.
What Are The Key Segments Within The Global Plasma Fractionation Market?
The plasma fractionation market covered in this report is segmented –
1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors
2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology
3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes
Subsegments:
1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)
3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)
4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)
Pre-Book The Plasma Fractionation Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Plasma Fractionation Market?
Leading firms in the sector are bringing out innovative technologies such as high-tech facility procedures that efficiently and safely convert donated human plasma into essential medicines. For example, in March 2023, the German-based company, CSL Behring, launched a new plasma fractionation facility, worth $470 million, that employs state-of-the-art technology to enhance the efficiency and safety of plasma handling, leading to higher-grade and more reliable drugs. The facility aids in fulfilling the burgeoning demand by augmenting the availability of these vital medicines, thereby ensuring more patients get access to life-saving therapies. Thanks to the cutting-edge automation and self-cleaning mechanisms, it curbs the risk of contamination and boosts overall sanitary conditions, thereby heightening patient safety.
Who Are the Key Players in the Plasma Fractionation Market?
Major companies operating in the plasma fractionation market include:
• Baxter International Inc.
• Bio Products Laboratory Limited
• Biotest AG
• CSL Limited
• Grifols S. A
• ADMA Biologics Inc.
• Green Cross Corporation
• Hualan Bioengineering Inc.
• Intas Pharmaceuticals Ltd.
• Japan Blood Products Organization
• Kedrion S. P. A.
• Kamada Ltd.
• LFB Biomedicaments S. A. S
• Octapharma AG
• Sanquin Plasma Products B. V.
• Shanghai Raas Blood Products Co. Ltd.
• Takeda Pharmaceutical Company
• Terumo BCT
• China Biologic Products Holdings Inc.
• China National Biotec Group
• Emergent BioSolutions Inc.
• Bharat Serum Vaccines Limited
• Plasma Therapeutics
• Prothya Biosolutions B. V.
• BioPharma Plasma LLC
• BioLife Plasma Services LP
What are the Regional Insights into the Plasma Fractionation Market?
North America was the largest region in the plasma fractionation market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
